Clinical Trial Update: Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating trastuzumab deruxtecan for HER2-positive newly diagnosed metastatic esophageal, gastric, and gastroesophageal junction cancers; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Trastuzumab Deruxtecan (Enhertu) (trastuzumab deruxtecan)

Snippet

Sponsor: University of Chicago | Conditions: HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2 | Phase 2 | Status: NOT_YET_RECRUITING